Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too

Morin, Nathaniel P.

doi:10.1016/j.diabres.2020.108160

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In addition, GLP-1 receptor agonists can prevent or reduce the sustained hyperglycemia resulting from systemic inflammation related to COVID-19. 21 Nevertheless, the use of GLP-1 receptor agonists is not without risks; GLP-1-based therapies have been notoriously linked to gastrointestinal side effects, including nausea, vomiting, and diarrhea, which may complicate gastrointestinal symptoms in patients with COVID-19. 22 In addition, the use of GLP-1 receptor agonists have been infrequently associated with the development of acute kidney injury, particularly in patients with severe gastrointestinal adverse effects.…”

Section: Resultsmentioning

confidence: 99%

“…This effect may play a role in averting the activation of proinflammatory pathways (such as Toll‐Like Receptor 4‐Nuclear Factor Kappa B) due to endotoxemia 20 . In addition, GLP‐1 receptor agonists can prevent or reduce the sustained hyperglycemia resulting from systemic inflammation related to COVID‐19 21 …”

Section: Discussionmentioning

confidence: 99%

“… 20 In addition, GLP‐1 receptor agonists can prevent or reduce the sustained hyperglycemia resulting from systemic inflammation related to COVID‐19. 21 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis

Kow,

Ramachandram,

Hasan

2023

Health Science Reports

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis

Kow,

Ramachandram,

Hasan

2023

Health Science Reports

View full text Add to dashboard Cite

“…We present here that both the hypertension drugs (ACEIs and ARBs) and GLP-1 based T2D drugs may stimulate ACE2 expression, making them double edged sword in the treatment of COVID-19 patients in the population with obesity, diabetes, aging and other metabolic disorders ( 38 , 42 , 43 ). It remains to be determined whether their treatment also increases the expression of sACE2 in human subjects.…”

Section: Discussionmentioning

confidence: 98%

Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment

et al. 2021

View full text Add to dashboard Cite

“…Chronic hyperglycemia is a condition that impairs both antibody-mediated immunity and innate immunity. Chronic low-grade inflammation may contribute to diabetes by inducing insulin resistance, disrupting glucose control and elevating inflammatory markers [62][63][64]. An increase in IL-6 and C-reactive protein (RCP) levels was observed in diabetic individuals who had the SARS-CoV-2 virus.…”

Section: Hyperglycemia Is Associated With Covid-19 Severitymentioning

confidence: 99%

Developmental Impacts of Epigenetics and Metabolism in COVID-19

Naik,

Patel,

Sen

2024

JDB

View full text Add to dashboard Cite

Developmental biology is intricately regulated by epigenetics and metabolism but the mechanisms are not completely understood. The situation becomes even more complicated during diseases where all three phenomena are dysregulated. A salient example is COVID-19, where the death toll exceeded 6.96 million in 4 years, while the virus continues to mutate into different variants and infect people. Early evidence during the pandemic showed that the host’s immune and inflammatory responses to COVID-19 (like the cytokine storm) impacted the host’s metabolism, causing damage to the host’s organs and overall physiology. The involvement of angiotensin-converting enzyme 2 (ACE2), the pivotal host receptor for the SARS-CoV-2 virus, was identified and linked to epigenetic abnormalities along with other contributing factors. Recently, studies have revealed stronger connections between epigenetics and metabolism in COVID-19 that impact development and accelerate aging. Patients manifest systemic toxicity, immune dysfunction and multi-organ failure. Single-cell multiomics and other state-of-the-art high-throughput studies are only just beginning to demonstrate the extent of dysregulation and damage. As epigenetics and metabolism directly impact development, there is a crucial need for research implementing cutting-edge technology, next-generation sequencing, bioinformatics analysis, the identification of biomarkers and clinical trials to help with prevention and therapeutic interventions against similar threats in the future.

show abstract

Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too

Cited by 6 publications

References 9 publications

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis

Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment

Developmental Impacts of Epigenetics and Metabolism in COVID-19

Contact Info

Product

Resources

About